MRNA vs GMAB โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
MRNA Captures Institutional Edge (2โ2 Pillars ยท 5โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Moderna, Inc. Common Stock (MRNA) driven by superior Valuation, Momentum & Technical while GMAB counters with relative strength in Growth & Margin, Options & Structure. Fundamentally, MRNA trades at 23.0x Forward P/E with -80.8% operating margin (+29.2% YoY revenue) versus GMAB at 29.3x Forward P/E and 30.6% operating margin (+16.1% YoY). In options structure, MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro) against GMAB sits in UNCLASSIFIED (9th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MRNA | GMAB | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $80.7B | $31.7B | Larger Scale | MRNA |
| Trailing P/E Ratio Valuation | 23.0x | 43.9x | Lower Multiple | MRNA |
| Forward P/E Ratio Valuation | 23.0x | 29.3x | Lower Multiple | MRNA |
| Revenue Growth (YoY) Growth | +29.2% | +16.1% | Higher Growth | MRNA |
| Operating Margin (TTM) Profitability | -80.8% | 30.6% | Higher Margin | GMAB |
| Net Profit Margin Profitability | -110.5% | 17.0% | Higher Margin | GMAB |
| Return on Equity (ROE) Capital Efficiency | -34.5% | 12.1% | Higher ROE | GMAB |
| 52-Week Range Position Momentum | 67% ($22โ$281) | 74% ($24โ$60) | Stronger Trend | GMAB |
| Beta / 30D Volatility Risk Regime | 2.23ฮฒ ยท 78% Vol | 0.71ฮฒ ยท 106% Vol | Lower Realized Risk | MRNA |
| Unified Institutional Score Composite Signal | 40.3 / 100 (SELL) | 40.1 / 100 (SELL) | Higher Composite | Tie |